|EVOTF -- USA Stock|| |
USD 19.65 0.60 2.96%
Dr. Cord Dohrmann was Chief Scientific Officer and Member of the Management Board at Evotec AG since September 1, 2010. Dr. Dohrmann has spent over 20 years in biomedical research at academic institutions and in the biotech industry. He started his academic career in 1983 studying Biology at Tuebingen University in Germany and conducting research as a DAAD scholar at Duke University, Durham, USA. Dr. Dohrmann completed his MA thesis at the MaxPlanck Institute in Tuebingen and subsequently enrolled at the Harvard Medical School in Boston, USA, where he received his Ph.D. in Cell and Developmental Biology in 1996. Dr. Dohrmann continued his career as a Shiseido research fellow at the Massachusetts General Hospital in Boston before joining DeveloGen in 1999. He served the company in various management positions including CEO, leading DeveloGen from a startup to an internationally recognized metabolic disease company with a pipeline of innovative preclinical and clinical products for the treatment of diabetes and related disorders
Age: 52 Executive Since 2010
49 40 5 60 81 0 http://www.evotec.com
Dohrmann was advising the European Commission, the MaxPlanckInstitute as well as VC firms and authored and coauthored a number of publications and patents. Since December 2016, Dr. Dohrmann was serving as member of the Supervisory Board of Eternygen GmbH. In June 2017, he became a member of the Supervisory Board of Facio Therapies BV.